TriSalus receives FDA clearance for TriNav Advance liver embolization device

TriSalus Life Sciences, Inc.

FDA 510(k) clearance for TriNav Advance PEDD device announced Sept 22, 2026; limited market release in coming weeks.
TriNav Advance adds small-distal-vessel access via compatible microcatheter; two configurations: telescoping and high-flow.
Expands TriSalus portfolio beyond liver embolization; supports broader range of embolization procedures.
Company now has four FDA-cleared devices: TriNav, TriNav LV, Pancreatic Retrograde, and TriNav Advance.

Featured in Daily 8-K Digest

Selected #8 for 2026-09-22. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.